Arborvitae Health and Wellbeing Pty Limited has entered into a clinical trial which is currently being undertaken by Medlab Pty Ltd.
The clinical trial is a Phase IIa Double Blind Placebo Controlled Clinical Trial, investigating the efficacy and safety of Arborvitae’s Health and Wellbeing Supplement.
Medlab is a biotechnology company with an approved biologics laboratory facility, designed to research and develop new medicines in the biological arena, specifically targeting conditions previously thought out-of-realm for biological medicine. The sophistication of the lab facilities allows Medlab to expand into pharmaceutical and nutraceutical analytical work. Specifically, the laboratory supports pre-commercialisation, including clinical trials and bench work, enabling early phase drug discovery with the intention of creating first-in-class drugs.
Professor Luis Vitetta is the principal Medlab investigator overseeing the conduct of Arborvitae’s clinical trial.
Professor Vitetta was appointed as Director of Medical Research in February 2013 and is currently an Adjunct Professor at the University of Sydney, Sydney Medical School.
Professor Vitetta is often an invited speaker at numerous local and international conferences, having expertise in probiotics, nutraceuticals, clinical trials, integrative medicine as well as complementary and alternative medicine.
For further information, please visit: https://www.medlab.co/